Comunicados de prensa BioNTech Investor News Salud y ciencias de la vida — Feed RSS y monitoreo en vivo
PPN World indexa los comunicados de prensa de BioNTech Investor News y archiva cada publicación. Esta fuente está en silencio desde el 20 de agosto de 2026 — sus 57 comunicados indexados siguen disponibles, y una alerta te avisará en cuanto vuelva a publicar.
Sobre este feed
BioNTech Investor News forma parte de los más de 1,400 feeds de comunicados que PPN World monitorea de forma continua — una fuente en inglés centrada en el sector Salud y ciencias de la vida, clasificada bajo «Alemania» en nuestro índice por país. Cada comunicado se deduplica, se geolocaliza y se enriquece con un resumen de IA, y puedes añadir alertas de búsquedas guardadas sobre cualquier palabra clave que publique. El comunicado más reciente de nuestro índice se publicó el 20 de agosto de 2026; la fuente está en silencio desde entonces.
Sigue BioNTech Investor News en tiempo real en PPN World
Cada comunicado de BioNTech Investor News llega al cockpit segundos después de publicarse — deduplicado, clasificado, con alertas de búsquedas guardadas y resúmenes con IA, junto a más de 1,400 feeds. Prueba gratis de 72 h, sin tarjeta.
Iniciar la prueba gratis →Comunicados de BioNTech Investor News — archivo
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccinehace 8 h
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026hace 7 d
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNT…
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Updatehace 23 d
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clin…
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Updatehace 23 d
Conference call and webcast scheduled for August 4, 2026, at 8:00 a.m. EDT (2:00 p.m. CEST)
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officerhace 24 d
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme…
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officerhace 24 d
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme…
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Unionhace 29 d
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion dos…
- BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026hace 37 d
MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Add…
- BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026hace 37 d
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Ad…
- Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trialhace 89 d
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1…
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meetinghace 97 d
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam…
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meetinghace 97 d
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam…
Los comunicados más recientes de esta fuente se transmiten en vivo para los miembros de PPN World.
Preguntas frecuentes
¿Cómo seguir los comunicados de BioNTech Investor News en tiempo real?+
¿Con qué frecuencia se recogen los comunicados de BioNTech Investor News?+
¿Qué tipo de comunicados publica BioNTech Investor News?+
Feeds relacionados
- Presseportal
- PR-Inside
- lifePR (DE)
- PresseBox (DE)
- German Federal Government (Bundesregierung)
- Bayerische Staatsregierung (Bayerisches Landesportal)
- Medienservice Sachsen
- Baden-Württemberg Landesregierung (Alle Meldungen)
- Sachsen-Anhalt Landesportal (Pressemitteilungen der Ministerien)
- Schleswig-Holstein Landesregierung (Alle Medieninformationen)